DT-Web

DB00558 - Zanamivir


Identification
Name Zanamivir
Accession Number DB00558 (APRD00378)
Type small molecule
Description A guanido-neuraminic acid that is used to inhibit neuraminidase. [PubChem]
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 332.3098
Groups approved
Monoisotopic Weight 332.133199014
Pharmacology
Indication For the prevention and treatment of influenza A and B.
Mechanism of action The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.
Absorption Absolute bioavailability is very low following oral administration (2%). Following oral inhalation, bioavailability is 4% to 17%.
Protein binding Zanamivir has limited plasma protein binding (<10%).
Biotransformation Not metabolized
Route of elimination It is excreted unchanged in the urine with excretion of a single dose completed within 24 hours. Unabsorbed drug is excreted in the feces.Zanamivir is renally excreted as unchanged drug.
Toxicity Not Available
Affected organisms
  • Influenza A virus
  • Influenza B virus
Interactions
Drug Interactions Not Available
Food Interactions Not Available

Targets


Neuraminidase
Name Neuraminidase
Gene Name NA
Pharmacological action yes
Actions inhibitor
References
  • Macdonald SJ, Cameron R, Demaine DA, Fenton RJ, Foster G, Gower D, Hamblin JN, Hamilton S, Hart GJ, Hill AP, Inglis GG, Jin B, Jones HT, McConnell DB, McKimm-Breschkin J, Mills G, Nguyen V, Owens IJ, Parry N, Shanahan SE, Smith D, Watson KG, Wu WY, Tucker SP: Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem. 2005 Apr 21;48(8):2964-71. - Pubmed
  • Murrell MT, Porotto M, Greengard O, Poltoratskaia N, Moscona A: A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity. J Virol. 2001 Jul;75(14):6310-20. - Pubmed
  • Mungall BA, Xu X, Klimov A: Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays. Avian Dis. 2003;47(3 Suppl):1141-4. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
DTHybrid score 1.395
Neuraminidase
Name Neuraminidase
Gene Name NA
Pharmacological action yes
Actions inhibitor
References
  • Eiland LS, Eiland EH: Zanamivir for the prevention of influenza in adults and children age 5 years and older. Ther Clin Risk Manag. 2007 Jun;3(3):461-5. - Pubmed
  • Oakley AJ, Barrett S, Peat TS, Newman J, Streltsov VA, Waddington L, Saito T, Tashiro M, McKimm-Breschkin JL: Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses. J Med Chem. 2010 Aug 9. - Pubmed
DTHybrid score 1.395
Sialidase-2
Name Sialidase-2
Gene Name NEU2
Pharmacological action unknown
Actions inhibitor
References
  • Chavas LM, Kato R, Suzuki N, von Itzstein M, Mann MC, Thomson RJ, Dyason JC, McKimm-Breschkin J, Fusi P, Tringali C, Venerando B, Tettamanti G, Monti E, Wakatsuki S: Complexity in influenza virus targeted drug design: interaction with human sialidases. J Med Chem. 2010 Apr 8;53(7):2998-3002. - Pubmed
DTHybrid score 1.4597

Predictions


Id Partner name Gene Name Score
641 Neuraminidase NA 1.395
2676 Neuraminidase NA 1.395
3026 Neuraminidase NA 1.395
3519 Neuraminidase NA 1.395
4335 Trans-sialidase Not Available 0.0712
5481 Trans-sialidase TCTS-154 0.0712
3140 Hemagglutinin-neuraminidase HN 0.0697
3609 Hemagglutinin-neuraminidase HN 0.0697
1141 Sialidase-1 NEU1 0.0645
2942 Sialidase nanH 0.0605
3546 Sialidase nedA 0.0605
4604 Liver carboxylesterase 1 CES1 0.0308
2164 Multidrug resistance-associated protein 4 ABCC4 0.0245
1539 Oligopeptide transporter, small intestine isoform SLC15A1 0.0237
6142 Solute carrier family 22 member 8 SLC22A8 0.0222
↑